Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Real-World data sought on new lung cancer drug IBI351

NCT ID NCT07198620

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 33 times

Summary

This study will review medical records of 600 Chinese patients with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called KRAS G12C. All patients received the drug IBI351 between August 2024 and August 2025. Researchers will measure how many patients' tumors shrink or disappear after treatment, and track side effects and survival times. The goal is to understand how well IBI351 works in everyday medical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University,

    Guangzhou, Guangdong, 510080, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.